AstraZeneca Gives FDA More Data On Brilinta Interaction With High-Dose Aspirin
This article was originally published in The Pink Sheet Daily
Executive Summary
In replying to FDA's December "complete response," company reaffirms its view that U.S. efficacy in the pivotal PLATO study was undercut by high doses of concomitant aspirin.